DexCom, Inc. $DXCM Stock Position Lessened by Savant Capital LLC

Savant Capital LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 57.6% in the 4th quarter, HoldingsChannel reports. The firm owned 14,350 shares of the medical device company’s stock after selling 19,456 shares during the quarter. Savant Capital LLC’s holdings in DexCom were worth $952,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of DXCM. Holocene Advisors LP bought a new position in shares of DexCom in the third quarter worth $163,964,000. CIBC Private Wealth Group LLC lifted its holdings in shares of DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after buying an additional 2,294,709 shares during the period. Vanguard Group Inc. lifted its holdings in shares of DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares during the period. Intermede Investment Partners Ltd acquired a new stake in shares of DexCom in the fourth quarter valued at $60,351,000. Finally, Iron Triangle Partners LP acquired a new stake in shares of DexCom in the third quarter valued at $57,196,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 1.9%

NASDAQ:DXCM opened at $73.45 on Wednesday. The firm has a market capitalization of $28.34 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 1.24 and a beta of 1.45. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The business’s fifty day moving average price is $64.32 and its 200 day moving average price is $66.64.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 earnings per share. On average, sell-side analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares in the company, valued at approximately $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 32,871 shares of company stock valued at $2,306,638. Company insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. Bank of America cut their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. TD Cowen cut their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 1st. Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. BTIG Research restated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Finally, Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $82.42.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.